

Day 2 May 20 (Thu.)

Plenary Session Scientific Program Educational Session Free Papers(Oral) Social Event English Session Live-Stream Session

		7:00	8:00	9:00	10:00	11:00	12:00	13:00	14:00	15:00	16:00	17:00	18:00	19:00	20:00	21:00	
Kyoto International Conference Center	Room 01 Main Hall (1F)		Web Hot Topics 02 Goal image of Stroke and Cardiovascular Disease Control Act				LS-13 Eli Lilly Japan K.K. / Daiichi Sankyo Co., Ltd.	Web PL Plenary Lecture	Web Pr President Lecture	Web AW Japanese Society of Neurology 2020 Award Winner Lecture		Web Symposium 20 Cutting-edge advances in NMOSD and MOG-related disorders					
	Room 02 Annex Hall 1 (1F)		Hot Topics 03 Drug discovery for myelopathy based on the pathomechanism of neurodamage		O-12 Cerebrovascular disease3		LS-14 Sumitomo Dainippon Pharma Co., Ltd.					Hot Topics 05 Overcome the challenges of cerebellar ataxia					
	Room 03 Annex Hall 2 (1F)		LM-03 Lecture Marathon 03	LM-04 Lecture Marathon 04	O-13 Parkinsonism and Related disorders 2		LS-15 Biogen Japan Ltd. / Eisai Co., Ltd.					LM-05 Lecture Marathon 05	LM-06 Lecture Marathon 06				
	Room 04 Room A (2F)		Web Symposium 13 Will new migraine medications save migraine patients?		O-14 Epilepsy 1		LS-16 Alexion Pharma GK			Web SPL-01 Semi-Plenary Lecture 01		Web Neuroscience Frontier Symposium 02 Frontiers of neuroscience and medicine accelerated by big data and AI					
	Room 05 Room B-1 (2F)		Web Hot Topics 04 Interdisciplinary research between dementia and epilepsy		O-15 Dementia 2		LS-17 Department of Medical Affairs, Otsuka Pharmaceutical Co., Ltd.					Web Neuroscience Frontier Symposium 03 Reassessment APOE4 in Alzheimer's disease			ES-01 Novartis Pharma K.K.		
	Room 06 Room B-2 (2F)		Web Symposium 14 Diagnosis and Treatment of Essential Tremor		O-16 Motor neuron disease 2		LS-18 Sanofi K.K.					Web Hot Topics 06 New diagnostic and therapy strategies for PSP/CBD					
	Room 07 Room D (1F)		Symposium 15 Recent advances in diagnostic methods and treatments for amyloidosis		O-17 Neuromuscular junction disorders		LS-19 NIHON PHARMACEUTICAL CO.,LTD.					Web Symposium 21 Novel molecular target drugs for MG: How should we use them?			ES-02 ONO PHARMACEUTICAL CO.,LTD.		
	Room 08 Room E (1F)		Symposium 16 Neuronal intranuclear inclusion disease and related disorders -update-		O-18 Neuropathology		LS-20 Pfizer Japan Inc.					Symposium 22 What are the hot topics of basic research related to Neurology?			ES-03 Mitsubishi Tanabe Pharma Corporation		
	Room 09 Sakura Hall (1F)		Symposium 17 The Mission of Music Therapy in Neurology		O-19 Clinical trial and Regenerative medicine1		LS-21 Japan Medical Office, Takeda Pharmaceutical Company Limited					Symposium 23 Role of Neurologists in the new stroke systems of care					
	Room 10 Swan Hall (1F)		Symposium 18 Neurological symptoms developing after intensive care: Post Intensive-Care Syndrome (PICS) and ICU-acquired weakness (ICUAW)		O-20 Parkinsonism and Related disorders 3		LS-22 Medical HQs, Eisai Co., Ltd.					Symposium 24 Multiple system degeneration and its clinical relevance in amyotrophic lateral sclerosis					
	Room 11 Room 157 (1F)		Symposium 19 Future-oriented working style reform for neurologists		O-21 Neuroimaging 1		LS-23 Nihon Medi-Physics Co.,Ltd.					Symposium 25 What neurologists can do for the next-generation intractable disease medical system					
	Room 12 Room C-1 (1F)				O-22 Neuroimmunology 2		LS-24 Astellas Pharma Inc.										
	Room 13 Room C-2 (1F)				O-23 Clinical Neurophysiology 2		LS-25 ONO PHARMACEUTICAL CO., LTD.										
	Room 14 Room 553 (5F)				O-24 Medical care for intractable diseases and others												
Poster Session New Hall (1F)		Poster Preparation / Poster Viewing				Poster Discussion	Poster Viewing						Poster Discussion	Poster Removal			

DAY 2